RESEARCH IMPACT

Hamilton Health Sciences Research

2024-25

Healing through discovery

As one of Canada's largest and top-ranked academic health sciences centres, Hamilton Health Sciences (HHS) plays a pivotal role in advancing health research, delivering exceptional care, and contributing to the vitality of our region and province.

At HHS, research is not a stand-alone activity — it's deeply embedded in how we care for patients, attract and develop top talent, and shape the future of health. Across a wide range of specialties, our teams are generating new knowledge and turning discovery into real-world solutions that address the evolving needs of our health system.

In 2024–25, we took important steps to expand the reach and impact of our research. This includes the launch of Explore Research, a new initiative connecting more patients with research opportunities. We also laid the foundation for two new institutes: the McMaster Children's Health Research Institute, and very recently the Centre for Discovery in Cancer Research becoming a joint HHS-McMcMaster University research centre.

As we develop HHS' new strategic plan, research will remain a key enabler - strengthening our role as a system leader, a hub of expertise and learning, and a provider of excellent, evidence-based care.

I'm proud to share HHS' 2024–25 Research Impact Report, a snapshot of HHS' passion, innovation, and lasting contributions to the health and well-being of the people we serve, both locally and far beyond.

On behalf of HHS' senior leadership team, thank you to everyone across the HHS community who makes this work possible. I'm excited to see what we'll achieve together in the year ahead.

Dr. Marc Jeschke
Vice President, Research &
Chief Scientific Officer

A Top 10 Canadian Research Hospital for over 10 years

Ontario's 2nd largest research and teaching hospital

RESEARCH SPENDING FY 2023/24
$207 million

RESEARCH PUBLICATIONS ANNUALLY
2,700 +

RESEARCHERS
850 +

RESEARCH SPACE
250,000 square feet

MEMBER INVESTIGATORS, RESEARCH STAFF & TRAINEES
2,700 +

CATALOGUED TISSUE SAMPLES IN CANADA'S **LARGEST BIOBANK**
4.1 million

RESEARCH STAFF
1,000 +

CLINICAL TRIAL PARTICIPANTS
1.3 million worldwide

ACTIVE RESEARCH STUDIES
2,000 +

GLOBAL HOST SITES CONDUCTING OUR RESEARCH TRIALS
1,600

Population Health Research Institute

Celebrating 25 years of PHRI research

World-leading health research is happening right here in Hamilton, and has been for years through a critical partnership between Hamilton Health Sciences and McMaster University. The **Population Health Research Institute (PHRI)**, which celebrated its 25th anniversary in 2024, attracts top-tier research and medical talent to Hamilton, says Dr. Hertzel Gerstein, PHRI interim executive director. PHRI has created hundreds of well-paying jobs, managed hundreds of millions of research dollars, and made cutting-edge discoveries benefiting patients locally and globally.

Here are just some of PHRI's many achievements:

Affordable heart disease prevention

A low-cost combination pill, known as the polypill, was shown to reduce heart attacks and deaths by one third, and it's now included in the World Health Organization (WHO)'s essential medicines list.

Heart protection

The drug ramipril, as well as related drugs, can significantly reduce heart attacks, strokes, and heart-related deaths in high-risk individuals. This led to approvals in over 40 countries and inclusion in guidelines for cardiovascular prevention.

"PHRI's research helps patients. It helps the city. It helps the country, and it helps the world. I think that's a huge story that needs to be shared widely."

– Dr. Hertzel Gerstein

Better heart attack treatment

Adding the medication clopidogrel to aspirin for patients with acute heart issues significantly lowers the risk of heart attacks, strokes, and heart-related deaths. This combination was incorporated into practice guidelines and received widespread regulatory approvals around the world.

Understanding heart attack risks

PHRI researchers identified nine major risk factors that are responsible for over 90 per cent of heart attacks globally, leading to their inclusion in health guidelines by the WHO.

Identifying stroke risks

Ten simple risk factors were found to be associated with about 90 per cent of strokes worldwide, and these findings are now part of global health guidelines.

Global heart health insights

Cardiovascular disease and death rates are higher in poorer countries and rural areas, even though they have fewer risk factors. This may be due to lower education and limited access to basic, proven treatments. Major risk factors include both indoor and outdoor air pollution.

Preventing strokes in atrial fibrillation patients

Drugs like dabigatran and apixaban, and combinations like clopidogrel with aspirin, better prevent strokes compared to older treatments for patients with irregular heartbeats.

New blood thinner strategy

A new strategy combining low-dose rivaroxaban with aspirin optimally reduces heart attacks, strokes, amputations, and deaths in certain heart patients. This approach is now widely approved.

Research Snapshot *2024*

Population Health Research Institute (PHRI)

RESEARCHERS **56 and 8 research fellows**
STAFF **315**
CURRENT STUDIES **63**
JOURNAL ARTICLES **566**
GRANTS **78**
PARTNER ORGANIZATIONS **53**
REACH **105** countries

Read the full story

Photo Opposite: Dr. Ashkan Shoamanesh, Senior Scientist
Photo Above: Dr. Sonia Anand, Senior Scientist

The many hats of a sepsis researcher

Dr. Alison Fox-Robichaud's passion for research dates back to her teenage years, when she began spending her summers working at a research lab.

"From the time I graduated high school, and every summer in university, I worked in a lab," recalls Fox-Robichaud, who went on to build an illustrious career as a Hamilton Health Sciences (HHS) critical care physician, national sepsis expert and researcher at the **Thrombosis & Atherosclerosis Research Institute (TaARI)** of HHS and McMaster University. She is a McMaster professor of medicine, HHS chair in sepsis research, HHS director of medical education, and scientific director for Sepsis Canada.

Fox-Robichaud cares for critically ill patients, including people with sepsis, in HHS Hamilton General Hospital's intensive care unit (ICU), while also researching sepsis. Her leading-edge research focuses on saving lives and improving the quality of life for sepsis patients and survivors, and she is accomplishing this through various unique and highly-impactful approaches.

Her many research projects over the years included being site lead for large Canadian Institutes of Health Research studies and leading some industry-funded studies.

She is currently the lead for an HHS drug repurposing study looking at treating patients with sepsis in the ICU. She is also the local

"Some of the research I'm most passionate about is finding tools to more quickly recognize sepsis."
– Dr. Alison Fox-Robichaud

principal investigator for another three clinical trials currently underway, and one about to start.

Over the past few years, Fox-Robichaud also became involved in health services research, related to reducing sepsis rates. Preventing hospital-acquired sepsis is a strategic priority for HHS. One of her early health services projects was the development of the Hamilton Early Warning Score (HEWS) at HHS. HEWS is used by hospital care teams to recognize the early signs of diseases in order to intervene and manage them early.

Fox-Robichaud is also passionate about research aimed at supporting sepsis survivors. "I'm very interested in studies looking into how we can help our sepsis survivors at HHS."

Research Snapshot *2024*

Thrombosis and Atherosclerosis Research Institute (TaARI)

RESEARCHERS **12**
STAFF **76**
TRAINEES **114**
CURRENT STUDIES **28**
JOURNAL ARTICLES **186**
GRANTS **56**
GRANTING AGENCIES/INDUSTRY PROJECTS **25+**
REACH **20+** countries



Read the full story

Photo: Dr. Alison Fox-Robichaud, left

Driving quality of life after CAR T-cell therapy

Hamilton Health Sciences (HHS) researcher and malignant hematologist Dr. Amaris Balitsky is studying the lasting impacts of CAR T-cell therapy, which became available to Ontario patients with certain types of lymphoma just five years ago.

In 2020, HHS Juravinski Hospital and Cancer Centre (JHCC) became the first hospital in Ontario to provide CAR T-cell therapy for patients with lymphoma, and the first hospital in Canada to offer this treatment on an outpatient basis. CAR T-cell therapy can knock lymphoma into remission, even for some patients previously considered incurable. But because the treatment is so new, it's not yet understood what lies ahead for survivors in the months and years after treatment.

Balitsky's research focuses on identifying long-term complications and offering solutions to help survivors enjoy the best quality of life.

CAR T-cell therapy is an immunotherapy that involves changing a patient's T-cells in a laboratory so they'll attack cancer cells. As with many therapies, there's a ripple effect. For example, CAR T-cell therapy creates a cytokine storm, which happens when the body releases chemicals called cytokines that can trigger a variety of symptoms, including inflammation of the brain.

"While we know that this brain swelling is mostly reversible, it's also the side effect that patients are most concerned about," says

“We’re learning from today’s patients, to hopefully help them have the best outcomes as well as building an improved quality of life for tomorrow’s patients.”
– Dr. Amaris Balitsky

Balitsky, a researcher with the **Escarpment Cancer Research Institute**, a joint institute of HHS and McMaster University. Her research is looking at whether such inflammation, even when short-term, can cause longer-term cognitive issues.

In search of answers, Balitsky is recruiting 40 JHCC patients for an HHS Foundation-funded study looking at long-term cognition in lymphoma patients who receive CAR T-cell therapy. The first year of data is expected in January 2026.

Balitsky is also studying geography related to CAR T-cell therapy, using patients’ postal codes. And a CAR T-cell registry that Balitsky created and maintains is an important tool in supporting leading-edge research studies. For example, a study led by Balitsky that’s now complete and under review for publication used the registry to better understand the rate of secondary cancers following CAR T-cell therapy.

Research Snapshot 2024
Escarpment Cancer Research Institute (ECRI)

RESEARCHERS **38**
STAFF **3**
TRAINEES **50**
CURRENT STUDIES **8**
JOURNAL ARTICLES **309**
GRANTS **56**
PARTNER ORGANIZATIONS **17**
REACH **71+** publications in international journals

Read the full story

Photo: Dr. Amaris Balitsky, left

Placing frailty scores at docs’ fingertips

The ever-growing amount of information added daily to Hamilton Health Sciences’ (HHS) state-of-the-art Epic hospital information system is making it possible to identify and rate patients for frailty, so they receive the best and most appropriate care.

Dr. Justin Lee, a geriatrician with HHS St. Peter’s Hospital, will be working with HHS’ health information technology services to create a frailty scoring system within Epic. Scores would give HHS clinicians such as doctors, nurses, social workers, occupational therapists and physiotherapists a full picture of patients’ frailty, so they can best support them, says Lee, a researcher with the **Geras Centre for Aging Research**, a centre at HHS that’s affiliated with McMaster University.

Lee is leading this research project in partnership with Geras and the McMaster Institute for Research on Aging.

Located at HHS St. Peter’s Hospital, Geras has a decade-long track record of making discoveries that change how health care is delivered to older adults locally and globally.

When a person is frail, their body has less resilience to bounce back from illness. Knowing how frail someone is can aid in forming a treatment plan and accessing resources and support for activities of daily living.

While there are existing tools, such as detailed checklists that doctors can use to measure frailty, they’re time consuming

> "Using this frailty score, we can take a more personalized and targeted approach to help our frail patients."
> **– Dr. Justin Lee**

and need to be done in-person during an appointment. Plus, they're not routinely used.

"Meanwhile, clinicians input patient information into Epic every day, but these data are generally underutilized," says Lee. "We know this information can be used to measure a patient's level of frailty, to help their clinician understand the full picture of their needs, and why they may be having difficulties."

Consultations are currently underway with HHS clinicians responsible for inputting patient information into Epic. A data analyst will then work to create an algorithm for pulling information together and calculating a frailty score.

"All of the potential is there thanks to Epic," says Lee. "Now we are concentrating on tapping into that, to advance care for our patients living with frailty."

Research Snapshot 2024
Geras Centre for Aging Research

RESEARCHERS **25**
STAFF **19**
TRAINEES **42**
CURRENT STUDIES **17**
JOURNAL ARTICLES **307**
GRANTS **36**
PARTNER ORGANIZATIONS **35+**
REACH Access to Geras toolkits in **73** countries

Photo: Dr. Justin Lee, left

Studying how Canadian kids were affected by the pandemic

Thanks to efforts spearheaded by the **Offord Centre for Child Studies** – a research institute affiliated with Hamilton Health Sciences and McMaster University – Canadian researchers and policy makers now have access to a wealth of information that can be used to study the health and well-being of children and youth in Canada pre and post-pandemic.

Offord Centre researchers, with the support of a $3.1-million grant from the Canadian Institutes of Health Research (CIHR) and additional funding from Statistics Canada and the Public Health Agency of Canada, made it possible to track the health of thousands of children and youth coast-to-coast before and after the pandemic, from 2019 to 2023, and compare findings, says Dr. Kathy Georgiades, Offord Centre member and McMaster professor who holds the David R. (Dan) Offord Chair in Child Studies.

Researchers call this a longitudinal study because it follows the same group of people over time to look for any changes in their health. Last fall, Statistics Canada released data from the longitudinal component of the 2023 Canadian Health Survey on Children and Youth (CHSCY) to the Canadian research community. The survey is a follow-up to the 2019 CHSCY, involving more than 41,000 children and youth ranging in age from one to 17. Those same young people, now five to 21 years old, were invited to participate in the 2023 survey.

"This data can help determine how to best invest resources so we're helping children and families who have been impacted the most."

– Dr. Kathy Georgiades

The idea for a large, national longitudinal study on the pandemic's impact on children and youth came from the Offord Centre, whose researchers secured CIHR funding to make the longitudinal component of the 2023 survey possible, and designed the survey in partnership with Statistics Canada and the Public Health Agency of Canada.

"The next time our country faces a pandemic, we'll be better prepared to support and protect these groups," says Georgiades, who led the Offord Centre's efforts to secure funding and initiate the longitudinal component of the 2023 CHSCY.

Research Snapshot 2024
Offord Centre for Child Studies

RESEARCHERS **15**
STAFF **72**
TRAINEES **64**
CURRENT STUDIES **33**
JOURNAL ARTICLES **113**
GRANTS **10**
PARTNER ORGANIZATIONS **134+**
REACH **9+** countries

Read the full story

World-first burn research will improve recovery

Two research studies currently underway at Hamilton Health Sciences (HHS) **Centre for Burn Research** could improve survival rates and quality of life for people with severe burns.

The first study, a Health Canada-approved Phase 1 clinical trial, involves harvesting stem cells from a patient's own burned skin tissue for treatment. The second study aims to close the gap in survival rates between older and younger patients with severe burns.

The stem cell study will evaluate the safety and feasibility of using stem cells harvested from a patient's own burned skin tissue to heal wounds. It could lead to a less invasive treatment for patients with burns to much of their body, improving their survival and healing rates, and bringing a better quality of life.

"Our hope, through this Phase 1 clinical trial, is to help patients with deep, extensive burns heal without further surgery and with less side effects like scarring because people heal better with their own stem cells," says Dr. Marc Jeschke, a globally recognized burn surgeon and researcher. Jeschke joined HHS in 2022 and established the HHS Centre for Burn Research. He also serves as vice president of research for HHS and is the hospital's chief scientific officer.

The second study focuses on older patients with severe burns. "Where a young adult or middle-aged patient might have a 20 per cent chance of dying from a severe burn injury, a patient aged 60 or older would have a 70 or 80 per cent chance of dying with the same burn size and injury severity," says Jeschke.

> “With the launch of the Phase 1 clinical trial, our lab will be the first in the world to treat patients using stem cells taken from their burned skin to help them heal.”
> **– Dr. Marc Jeschke**

The HHS burn team’s cutting-edge research into the link between metabolism and aging could help narrow the gap in survival rates. Jeschke’s lab is exploring the use of biologic medicines to induce certain rejuvenating cells and organs into promoting the energy needed for healing after a burn injury.

“Our goal, through this research, is to narrow the gap so that older burn patients survive their injuries, and heal in a way that allows them to enjoy a good quality of life.”

Research Snapshot 2024

Centre for Burn Research

RESEARCHERS **8**
STAFF **13**
TRAINEES **10**
CURRENT STUDIES **15**
JOURNAL ARTICLES **20**
GRANTS **4**
PARTNER ORGANIZATIONS **8**
REACH **8+** countries

Read the full story

Photo: Dr. Marc Jeschke

HHS recognized for world-class blood analysis

A Hamilton Health Sciences (HHS) research lab has earned an international designation as an Olink certified service provider for its expertise in proteomics.

With traditional bloodwork, a handful of tests may be ordered to look for diseases or help determine the state of a person's health. "But with proteomics, the technology has advanced to the point where up to 5,000 blood biomarkers can be identified from a single blood sample," says Dr. Guillaume Paré, a medical biochemist and director of the *HHS Clinical Research Laboratory and Biobank – Genetic and Molecular Epidemiology Laboratory (CRLB-GMEL)*.

"This certification recognizes the CRLB-GMEL as an international leader in proteomics," says Paré. "By including our lab in its list, Olink is confirming that the work we do meets the highest international quality standards."

Olink is a global leader in proteomics, and researchers from around the world rely on its highly specialized lab work for their studies. Of the four Canadian labs to be named Olink certified service providers, only two offer the full spectrum of Olink services – the Hamilton lab, and a lab at Montreal's McGill University.

For Canadian researchers, the HHS lab's designation means they are guaranteed high-quality proteomics blood analysis services in their own country, so they don't need to send samples to Sweden. For HHS researchers, Olink-quality services are available right here at home, by their colleagues.

> “This certification helps place HHS at the forefront of innovation.”
>
> **– Dr. Guillaume Paré**

The CRLB-GMEL provides a broad range of cutting-edge genomics and proteomics services, and specializes in large-scale population genetic studies. Services are available to HHS and McMaster researchers, as well as researchers nationally and internationally.

“Each biomarker tells us a story about how well someone is doing, or potential diseases this person could be afflicted with,” says Paré, who is also deputy director of the Thrombosis and Atherosclerosis Research Institute and a senior scientist with the Population Health Research Institute.

Paré says that eventually, this technology could expand from the research world to patient care. And as an Olink certified service provider, HHS will be well-positioned to be a leader in using this technology to directly benefit patients.

Research Snapshot 2024
CRLB-GMEL

RESEARCHERS **6**
STAFF **15**
TRAINEES **16**
SAMPLES BIOBANKED **4.1 million**
SAMPLES SHIPPED ANNUALLY **20,000 +**
COUNTRIES REPRESENTED **85**
STUDIES SUPPORTED TO DATE **400 +**
ANNUAL GRANTS **8**
ANALYTICAL DATA PROCESSED **200 + terrabytes**

Read the full story

Combatting high blood pressure in kids through big-data research

Young adults who had undiagnosed and unmanaged high blood pressure as children face a higher risk of suffering a life-threatening heart attack or stroke as early as their late twenties or early thirties, and their children are also at higher risk of developing hypertension.

High blood pressure, also called hypertension, is present in six to eight per cent of children and is becoming increasingly common. Yet studies show it's largely underdiagnosed.

Dr. Rahul Chanchlani is a pediatric kidney specialist at Hamilton Health Sciences' (HHS) McMaster Children's Hospital (MCH). He's leading a study aimed at developing an online screening tool, or calculator, that family doctors, pediatricians and even parents can use to predict risk and intervene early, so dangerous health complications due to hypertension can be prevented.

And because the study is international in scope, this innovative screening tool will have the potential to be used worldwide, preventing life-threatening illnesses and saving health-care systems millions of dollars.

An earlier study led by Chanchlani, published in JAMA Pediatrics in May 2024, found that Canadian children diagnosed with hypertension have twice the risk of having a major heart attack, stroke or even dying as early as their late 20s or early 30s.

Chanchlani's ALERT-BP study, made possible through funding from the HHS Foundation

> “We followed these children from 1996 to 2022, and found that those with high blood pressure were at twice the risk of having major cardiovascular events within 20 years of their diagnosis.”
>
> **– Dr. Rahul Chanchlani**

and Kidney Foundation of Canada, aims to develop a risk prediction tool, or calculator, for detecting high blood pressure in kids as young as five using data from birth cohort studies in Canada, the United States and the United Kingdom, and testing the prediction tool model in those countries. Two of the Canadian cohorts are in based in Hamilton.

If all goes well, this work will lead to the creation of a state-of-the art calculator that could be used by anyone from family doctors, to pediatricians, to parents, to predict risk. The calculator could also be integrated into electronic health records systems such as Epic, the hospital information system used by HHS. And because the study includes children from many diverse backgrounds, this tool has the potential to be used worldwide.

Research Snapshot *2024*
Children’s Health

- Research specializing in pre-birth to age 17
- Integrating leading-edge research into children’s health
- Plan launch of McMaster Children’s Health Research Institute
- Forming key research partnerships to support HHS McMaster Children’s Hospital families/children

Improving gynecological cancer outcomes

As people grow older, their risk of developing cancer increases. So does their risk of becoming frail. It's a dangerous combination, given that frailty affects up to 40 per cent of patients living with cancer, increasing their risk of both short and long-term side effects, and even death, following treatment.

When a person is frail, their body has less resilience to tolerate treatments and recover, says Dr. Julie Nguyen, a gynecologic oncologist at Hamilton Health Sciences' (HHS) Juravinski Hospital and Cancer Centre (JHCC), and a researcher who studies frailty in patients with gynecological cancers, such as cancers of the uterus, cervix and ovaries.

"This is why it's so important for cancer researchers to better understand frailty, and how to best measure it, so that we can tailor treatments to patients' individual needs, and develop interventions to help them grow stronger and live longer with the best possible quality of life," says Nguyen.

The FARGO (Frailty Assessment for Risk prediction in Gynecologic Oncology) study, co-led by Nguyen and senior researcher Dr. Maura Marcucci at the Population Health Research Institute (PHRI) aims to find better, more practical ways to assess frailty in patients with cancer as they go through treatment and recovery.

Nguyen and Marcucci are both researchers with PHRI and the McMaster Institute for Research on Aging. They're working on the study in collaboration with leading experts

> “Research shows that frail patients have shorter survival rates after being diagnosed with cancer and going through treatment.”
>
> **– Dr. Julie Nguyen**

from PHRI; the HHS Clinical Research Laboratory and Biobank – Genetic and Molecular Epidemiology Laboratory; and the gynecologic oncology and internal medicine teams at JHCC, Sunnybrook Health Sciences Centre, University Health Network and Credit Valley Hospital. The FARGO study is supported with funding from the HHS Foundation, among other funding sources.

“FARGO is one of the first studies to measure frailty at several time points in a patient’s treatment journey, and perhaps the first that seeks to find new blood tests for frailty in patients with gynecologic cancers,” says Nguyen.

“In the future, we hope to develop interventions to help frail patients become stronger before, during and after their treatments.”

Research Snapshot 2024
Women’s Health

- Transforming women’s health across lifespan
- Collaborating with St. Joseph’s Healthcare Hamilton and McMaster University to integrate clinical care with cutting-edge research to improve women’s health outcomes across various life stages.
- Advancing women’s health research, translating scientific discoveries into improved health care practices and policies



Congratulations 2024 DRIVE Spark winners

Three teams of innovators received 2024 *DRIVE Spark funding grants* from the hospital to support original, new projects aimed at improving health-care delivery. Each team was eligible for a grant of up to $50,000.

To help prevent falls, a team at the Geras Centre for Aging Research developed SixthSense, an innovative radar sensor that measures walking speed—the "sixth vital sign"—in less than six seconds. With support from this funding, the team is working to bring SixthSense into clinics.

Read the full story

Power of Play is the brainchild of two McMaster University engineering students, who recognized an opportunity to improve pediatric physical therapy by developing a kid-friendly tool to measure grip strength. They will leverage funding to further develop their product, produce a prototype and prepare for clinical testing.

Medloaner is a Hamilton company that provides AI-powered supply chain optimization of surgical procedure kits, to streamline how surgical devices are managed and processed within a hospital setting. Medloaner will use funding to further develop their technology with HHS.

Increasing research inclusivity and impact

All patients receiving care at Hamilton Health Sciences (HHS) are now automatically enrolled in *Explore Research*, the hospital's new patient recruitment process for research studies, unless they choose to opt out. Through Explore Research, patients have the opportunity to be contacted about potential research studies that may fit with their illness and treatment plan.

"The more patients willing to participate in studies, the greater the opportunities to advance human health," says Katie Porter, executive director of research strategy and operations for HHS. Porter led the teams responsible for bringing this new recruitment approach to the hospital.

No one will be registered for a study without giving consent, and all personal health information will remain confidential. Explore Research makes it easier and more equitable for individuals interested in taking part in research studies, and also expands our possibilities by connecting a wider pool of eligible candidates to groundbreaking research opportunities.

Read the full story

Photo: Katie Porter

HHS Research Leadership

Dr. Marc Jeschke,
Vice President, Research and Chief Scientific Officer

Dr. Ted Scott,
Vice President, Innovation and Partnerships

Dr. Hertzel Gerstein,
Executive Director (Interim), Population Health Research Institute

Dr. Greg Pond,
Director, Escarpment Cancer Research Institute

Dr. Jeffrey Weitz,
Executive Director, Thrombosis & Atherosclerosis Research Institute

Dr. Stelios Georgiades,
Director, Offord Centre for Child Studies

Dr. Alexandra Papaioannou,
Executive Director, Geras Centre for Aging Research

Dr. Guillaume Paré,
Director, HHS Clinical Research Laboratory and Biobank – Genetic and Molecular Epidemiology Laboratory

Dr. Sheila Singh,
Director, Centre for Discovery in Cancer Research

Dr. Gita Wahi,
Associate Chair, Research, Department of Pediatrics, McMaster University

Dr. Jon Barrett,
Chair, Department of Obstetrics and Gynecology, McMaster University

Katie Porter,
Executive Director of Research Strategy and Operations

Anthony Scandinavo,
Director, Research Finance

Hamilton Health Sciences Research

hamiltonhealthsciences.ca/research